SCHEMBL22290362

SCHEMBL22290362

Brc1cccc(OCC2CCOC2)c1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 1/20 0.45
ALDH1A1 P00352 1/20 0.45
TP53 P04637 1/20 0.45
CYP3A4 P08684 1/20 0.45
TSHR P16473 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HIF1A Q16665 1/20 0.45
MAOB P27338 6/20 0.44
XDH P47989 1/20 0.43
HRH3 Q9Y5N1 1/20 0.42
FFAR1 O14842 1/20 0.41
PPARG P37231 1/20 0.41
PPARD Q03181 1/20 0.41
GRM5 P41594 1/20 0.40
TRIM24 O15164 1/20 0.40
CYP2D6 P10635 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31173165 1.00 MCHR1 (0.45) MCHR1ALDH1A1TP53CYP3A4TSHR
SCHEMBL18706871 0.92 ALDH1A1 (0.43) ALDH1A1TP53CYP3A4TSHRSMN1; SMN2
SCHEMBL16031257 0.91 CYP2D6 (0.46) ALDH1A1TP53CYP3A4TSHRSMN1; SMN2
SCHEMBL22290928 0.88 ALDH1A1 (0.50) ALDH1A1TP53CYP3A4TSHRSMN1; SMN2
SCHEMBL31173243 0.88 ALDH1A1 (0.50) ALDH1A1TP53CYP3A4TSHRSMN1; SMN2
SCHEMBL931640 0.82 MAOB (0.53) ALDH1A1TP53CYP3A4TSHRSMN1; SMN2
SCHEMBL30074482 0.82 MAOB (0.53) ALDH1A1TP53CYP3A4TSHRSMN1; SMN2
SCHEMBL8277631 0.82 KDM4E (0.46) MCHR1ALDH1A1TP53CYP3A4TSHR
SCHEMBL16481481 0.81 XDH (0.49) MCHR1ALDH1A1TSHRMAOBXDH
SCHEMBL13462935 0.80 GRM2 (0.46) MCHR1ALDH1A1TP53CYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3917527-B1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-04-23 EP disclosed
US-20230079819-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-03-16 US disclosed
EP-3917527-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2021-12-08 EP disclosed
CN-113645971-A Compound and use thereof 福宏治疗公司 2021-11-12 CN disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 WO disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079819-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB MCHR1 4611/4885ALDH1A1 2571/4885TP53 908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.